In Kurogochi 2025 et al., on cardioplegia in mitral repair, what was concluded about long-term outcomes between groups?
A. mDN had higher survival at 700 days
B. Control group had better hospitalization outcomes
C. No differences in survival or hospitalization duration
D. mDN had lower discharge rates
E. mDN was associated with more complications
Answer: No differences in survival or hospitalization duration
Explanation: Survival at 700 days was 90% in both groups; hospital stay was median 6 days.
In Kurogochi 2025 et al., on cardioplegia in mitral repair, what difference was found in serum potassium at cross-clamp removal?
A. Potassium was higher in the mDN group
B. Potassium was equal between groups
C. Potassium was higher in control group
D. Potassium was below normal in both groups
E. Potassium was unmeasurable in mDN group
Answer: Potassium was higher in control group
Explanation: Potassium at cross-clamp removal was higher in control group (5.4 vs 4.5 mEq/L, p = 0.005).
In Kurogochi 2025 et al., on cardioplegia in mitral repair, what was the effect of mDN solution on sinus rhythm recovery?
A. It delayed sinus rhythm recovery compared to the control group
B. It had no significant impact on sinus rhythm recovery
C. It resulted in significantly faster sinus rhythm recovery
D. It led to a higher defibrillation rate
E. It caused arrhythmias post-cross-clamp
Answer: It resulted in significantly faster sinus rhythm recovery
Explanation: Faster sinus rhythm recovery in the mDN group (60s vs 362s, p = 0.027) suggests electrical stabilization benefits.
In Kurogochi 2025 et al., on cardioplegia in mitral repair, what was the main finding regarding serum cardiac troponin I levels 12 hours post-op?
A. They were significantly lower in the mDN group
B. They were significantly higher in the mDN group
C. They were comparable between both groups
D. Only control group showed elevation
E. Only mDN group showed elevation
Answer: They were comparable between both groups
Explanation: There was no significant difference in cTnI levels at 12h post-op (p = 0.478).
In Kurogochi 2025 et al., on cardioplegia in mitral repair, how did the number of cardioplegia doses differ between groups?
A. mDN group required more doses
B. Control group required fewer doses
C. Both groups required the same doses
D. mDN group received none
E. Dosing was not reported
Answer: Control group required fewer doses
Explanation: mDN group needed fewer total doses (median 2.5 vs 4, p = 0.040).